Please login to the form below

Not currently logged in
Email:
Password:

Shield Therapeutics’ CFO steps down

Richard Jones to leave the group in early 2017

Richard Jones is to step down from his position as chief financial officer at Shield Therapeutics early next year.

Jones joined the secondary care pharmaceutical specialist in 2010 as a non-executive director before taking on his current role a year later.

He brought nearly 30 years of financial management experience to the firm, with 16 years specialising in the healthcare sector.

Previously, Jones has served as a healthcare consultant for Grant Thornton's healthcare advisory practice, as a strategic advisory board member for Bionow and in a number of senior corporate finance roles specialising in healthcare.

Carl Sterritt, chief executive officer of Shield Therapeutics, said: “Richard has helped build the Group from its inception as a small private company through to being listed on AIM.

“I would like to thank him for his significant contribution to Shield and wish him the best in his future endeavours as we continue to grow rapidly into a commercial-stage specialty pharmaceutical business with international operations."


23rd November 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics